Core Viewpoint - The research reveals that IDO1 is a key regulator of ROS rhythm in tumor cells, proposing a dual inhibition strategy targeting both IDO1 and AhR to overcome cancer treatment resistance [3][10]. Group 1: IDO1 and ROS Dynamics - IDO1 is identified as a crucial regulator of the rhythmic changes in ROS levels within tumor cells, which oscillate approximately every 24 hours [5][6]. - The study demonstrates that IDO1 has a dynamic behavior, transitioning between the nucleus and cytoplasm based on ROS levels, challenging previous notions of its static localization [6]. Group 2: Mechanism of Action - Under low ROS conditions, IDO1 is degraded in the nucleus, while high ROS levels lead to its activation in the cytoplasm, where it catalyzes the conversion of tryptophan to kynurenine (Kyn) [6][7]. - Kyn not only binds to AhR to exert immunosuppressive effects but also activates the pentose phosphate pathway (PPP) by enhancing G6PD activity, creating a feedback loop that regulates ROS levels [7][8]. Group 3: Implications for Cancer Treatment - The findings explain the clinical failures of IDO1 inhibitors, as inhibiting IDO1 can inadvertently activate compensatory pathways that promote tumor growth [8]. - The proposed dual inhibition strategy targeting both IDO1 and AhR aims to enhance anti-tumor immunity while simultaneously inducing oxidative stress in tumor cells, showing significant tumor suppression effects in mouse models [10].